BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Epi proColon 2 diagnostic data

Epigenomics reported data from a U.S. validation study evaluating plasma samples selected from a cohort of 7,940 subjects who had an average risk for colorectal cancer and underwent colonoscopy showing that its Epi proColon 2.0 test had 68% sensitivity and 80% specificity for detecting colorectal cancer. The test cohort included 45 cases of colorectal cancer. Epigenomics said that although the results were at the lower end of the expected performance data, the findings confirm the results...

Read the full 360 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >